Betta Pharmaceuticals (300558.SZ): BPI-572270 capsules receive U.S. FDA approval for new drug clinical trial

Zhito Finance APP News: Betta Pharmaceuticals (300558.SZ) announced that recently, the clinical trial application for the BPI-572270 capsule drug submitted by the company's wholly-owned subsidiary, Hangzhou Jingyao Biotechnology Co., Ltd., was approved by the U.S. Food and Drug Administration (referred to as the "U.S. FDA"). The drug is intended for use in advanced solid tumors.